Drug
Iov 4001
Iov 4001: highest development phase Phase 1/2, developed by Iovance Biotherapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Iovance Biotherapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| IOV-4001 NCT05361174 | Phase 1/2 | Unresectable Melanoma |
Latest
No recent events.
Follow Iov 4001 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.